CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model
Dr. Yanan Wang (Leiden, The Netherlands)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Yanan Wang showed in a humanised animal model, the CETP-inhibitor anacetrapib reduced atherosclerosis development, by lowering non-HDL-c levels, via increased uptake in the liver. In addition, anacetrapib reduces plasma PCSK9 levels.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.